A novel liposome product, doxorubicin hydrocholoride liposomal injection, has received FDA approval as well as European Commission authorization to be used in the treatment of a variety of cancers, including ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi's sarcoma, and multiple myeloma. It is no doubt another piece of good news for patients as well as researchers...
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek